The Use of Vaginal Estrogen in Women with a History of Estrogen-Dependent Breast Cancer

Obstetrics and Gynecology

Volumn 127, Issue 3, 2016, Pages e93-e96

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; MEDICAL HISTORY; ONCOLOGIST; PRIORITY JOURNAL; RECURRENCE RISK; VAGINA RING; BLOOD; BREAST TUMOR; CONTRAINDICATIONS; INTRAVAGINAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVAGINAL; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS;

EID: 84960157979     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001351     Document Type: Article

References (22)

1. Rippy L, Marsden J. Is HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric 2006;9:404-15. [PubMed] [Full Text]
2. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33. [PubMed]
3. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:202-16. [PubMed] [Obstetrics & Gynecology]
4. Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: A randomized controlled trial. Obstet Gynecol 2014;123:1231-6. [PubMed] [Obstetrics & Gynecology]
5. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73. [PubMed]
6. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500. pub2. [PubMed] [Full Text]
7. Compounded bioidentical menopausal hormone therapy. Committee Opinion No. 532. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:411-5. [PubMed] [Obstetrics & Gynecology]
8. Lasley BL, Santoro N, Randolf JF, Gold EB, Crawford S, Weiss G, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab 2002;87:3760-7. [PubMed] [Full Text]
9. Schmidt G, Andersson SB, Nordle O, Johansson CJ, Gunnarsson PO. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 1994;38:253-60. [PubMed]
10. Mitchell ES, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: toward a more precise definition. Menopause 2000;7:334-49. [PubMed]
11. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144-8. [PubMed] [Full Text]
12. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-7. [PubMed]
13. Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989;27: 204-7. [PubMed]
14. Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9: 179-87. [PubMed]
15. Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187-97. [PubMed] [Full Text]
16. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673-81. [PubMed]
17. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case-control study. Breast Cancer Res Treat 2012;135:603-9. [PubMed]
18. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62. [PubMed] [Full Text]
19. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-31. [PubMed] [Full Text]
20. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-7. [PubMed] [Full Text]
21. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study. Gynecol Endocrinol 2010;26: 404-12. [PubMed] [Full Text]
22. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 119:666-82. [PubMed] [Obstetrics & Gynecology]